Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC

<div>Dynamics of brain metastases on osimertinib. Brain MRI (T1 with contrast, axial, and sagittal) showing brain metastases (white arrows) before treatment (a and c) and 1 month after initiating treatment (b and d).</div>

Journal of Oncology

fig2

Figure 2

Figure 2: Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLC 